Accenture has introduced new research and development services intended to help pharmaceutical companies deliver medical products to patients.
The company has invested more than $200 million in the Accelerated R&D Services suite that works to integrate research and development tasks for customers using cloud, mobility and analytics platforms, Accenture said Wednesday.
Services aim to help clients market pharmaceutical products through a pay-for-performance structure for business process outsourcing.
“An industry demand exists for new benchmarks that are driven by increasingly stringent health authority requirements, unsustainable fixed-cost models, and the complexity of managing numerous vendor partners and technology systems,” said David Boath, senior managing director of the suite for Accenture.
Boath added the new suite aims to complement Accenture’s acquisition of Octagon Research Solution, its recent evaluation by IDC Health Insights Drug Safety Services for clinical and pharmacovigilance operations and collaborations with cloud companies.
Accenture seeks to help customers identify patients, capture trial data and centralize data and reporting through the Clinical Data Interchange Standards Consortium criteria.
Cloud-based regulatory services use the CDISC standards and a unified processing platform to help clients manage regulatory quality and operations.
Pharmacovigilance services also work to build on mobile and web-based information for compliance.